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Balloon atrial septostomy (BAS) is a palliative 
procedure, but actually, interatrial shunt tends to 
be self-closing within a few months. However, in 
countries with a large number of donors, time to 
lung transplantation (LuTx) for a patient on a wait-
ing list it is approximately 2–4 months [2]. Such 
a short waiting time allows the procedure to be 
performed only once or even offers the possibility 
of extracorporeal membrane oxygenation if the pa-
tient requires bridging treatment [3]. In cases with 
an essentially longer waiting list, there is a need 
for methods which allow a deteriorating patient to 
survive for a year or even up to 2 years. Using one 
of the devices available on the market in addition 
to BAS, to keep the interatrial connection opened 
within this time period, prevents the patient from 
having the procedure repeated. These devices 
are very promising — especially the atrial flow 
regulator (AFR) invented by Vettukattil’s group [4]. 
However, currently, some significant disadvan-
tages exist comprising: i) the limited availability 
for commercial use, ii) high price and iii) lack of 
reimbursement for the procedure. 
Patients disqualified from LuTx would prob-
ably benefit significantly from the implantation 
of such a device as their life would be prolonged 
without the need for repeated invasive BAS pro-
cedure [5]. On the other hand, however, there 
are patients referred for LuTx for which another 
question arises: what to do with such devices in 
patients undergoing LuTx. The only device which 
is retrievable is the AFR. However, after a period 
of implantation, the device gets endothelialized 
and retrieval becomes impossible. Thus, the only 
remaining option seems to be an AFR closure 
with an atrial septal occluder or vascular plug. 
But when? During  transplantation or some time 
later? Perhaps such a patent connection between 
the atria could be helpful in the initial period after 
LuTx, because the flow direction in the shunt would 
reverse, causing a bigger preload and in this way 
improving its function before adapting to the lower 
vascular resistance of the new lungs. The current 
ongoing multicenter trial in which the AFR device 
is being tested will perhaps tell us more precisely, 
how to face these challenges.
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